My research aims to define and target molecular drivers of therapeutic resistance in cancers, with a focus on RAC2 mediated mechanisms in triple negative breast cancer. I am committed to developing biomarker guided strategies that will improve treatment precision and reduce cancer disparities. My long term goal is to work in translational oncology research, advancing innovative therapeutics and strengthening the scientific network through mentorship and collaboration.